ArticleEmerging infectious diseases2023
Tecovirimat Resistance in Mpox Patients, United States, 2022-2023.
Article in Emerging infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 112 citations in OpenAlex.
- Tecovirimat treatment of clade II mpox: a virological analysis of a randomised, double-blind, phase 3 trial.The Lancet. Microbe · 2026Trial
- Design, synthesis and antiviral activity of ciclopirox (CPX) analogs against orthopoxvirus.Bioorganic & medicinal chemistry · 2026Article
- The aminoadamantane derivative 3F2 modulates monocyte and NK cell activation and restores immune mediators altered by Monkeypox virus stimuli.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- The next generation of orthopoxvirus antivirals: preparing for future threats.Future medicinal chemistry · 2026Article
- Comment on "Efficacy of a Large Language Model Data Extraction System in Evidence Reviews for Emerging Infectious Diseases: A Randomized Crossover Trial".Open forum infectious diseases · 2026Article
- Monovalent Nondegrading Molecular Glues: An Updated Overview of Emerging Mechanisms and Therapeutic Development.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Mpox in Europe, 2022-2026: A Scoping Review of Viral Clades, Host Determinants of Severity and Antiviral Therapy.Viruses · 2026Article
- Overcoming Transmission Barriers: A Dual-Functional Adhesive Hydrogel for Direct Monkeypox Virus Neutralization and Wound Healing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Exploration of the protein and pharmacological landscape of monkeypox virus treatment: from entry point to end point.Molecular diversity · 2026Review
- MMF inhibits poxvirus infection by disrupting IMPDH2 interaction with USP5 and inducing its rod-and-ring assemblies.Virologica Sinica · 2026Article
- Efficacy of a Large Language Model Data Extraction System in Evidence Reviews for Emerging Infectious Diseases: A Randomized Crossover Trial.Open forum infectious diseases · 2026Article
- Recent advances in Mpox across innate immunity, evasion, and clinical outcomes.Communications biology · 2026Review
- Bruton's tyrosine kinase inhibitor BTKi-2 inhibits mpox virus and vaccinia virus infection.Virologica Sinica · 2026Article
- 3-Hydroxypyrimidine-2,4-dione derivatives as monkeypox virus resolvase (Mpr) inhibitors.RSC medicinal chemistry · 2026Article
- MPXV replication and drug resistance in CNS of advanced HIV case at autopsy.Research square · 2026Article
- An Emerging Global Threat After The COVID-19 Pandemic: Monkeypox Similarities and Differences.Polish journal of microbiology · 2026Review
- In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Conditional T and NK cell antagonism by a giant and highly conserved orthopoxvirus virulence factor.Research square · 2026Article
- Monkeypox Virus Shedding Despite Tecovirimat Treatment in a Cohort in Toronto, Canada.The Journal of infectious diseases · 2026Article
- 1-Hydroxy-1,8-napthyridinone (DHN) Analogs Potently Inhibit Monkeypox Virus Resolvase (Mpr).Journal of medicinal chemistry · 2026Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the 2022 multinational outbreak of monkeypox virus (MPXV) infection, the antiviral drug tecovirimat (TPOXX; SIGA Technologies, Inc., https://www.siga.com) was deployed in the United States on a large scale for the first time. The MPXV F13L gene homologue encodes the target of tecovirimat, and single amino acid changes in F13 are known to cause resistance to tecovirimat. Genomic sequencing identified 11 mutations previously reported to cause resistance, along with 13 novel mutations. Resistant phenotype was determined using a viral cytopathic effect assay. We tested 124 isolates from 68 patients; 96 isolates from 46 patients were found to have a resistant phenotype. Most resistant isolates were associated with severely immunocompromised mpox patients on multiple courses of tecovirimat treatment, whereas most isolates identified by routine surveillance of patients not treated with tecovirimat remained sensitive. The frequency of resistant viruses remains relatively low (<1%) compared with the total number of patients treated with tecovirimat.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.